行情

BLRX

BLRX

BioLine RX
NASDAQ

实时行情|Nasdaq Last Sale

1.910
-0.439
-18.69%
盘前: 2.000 +0.09 +4.70% 08:45 08/07 EDT
开盘
2.190
昨收
2.349
最高
2.200
最低
1.880
成交量
3,970
成交额
--
52周最高
3.642
52周最低
1.061
市值
3,775.54万
市盈率(TTM)
-0.7755
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BLRX价格均价为11.33,最高价位18.00,最低价为5.00。

EPS

BLRX 新闻

更多
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2020 and provides a corporate update.
PR Newswire · 1天前
BioLineRx Granted Australian Patent Number 2014343214 Titled 'Methods of treating acute myeloid leukemia with a FLT3 mutation'
https://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2014343214#
Benzinga · 1天前
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020, before the US mark
PR Newswire · 07/31 11:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
Zacks · 07/24 17:08
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
Zacks · 07/08 13:43
Acceleron (XLRN) in Focus: Stock Moves 5.3% Higher
Zacks · 07/06 13:50
Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher
Zacks · 07/02 13:53

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

BLRX 简况

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
展开

微牛提供BioLineRX Ltd.(NASDAQ-BLRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BLRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BLRX股票基本功能。